Drug Shortage Report for TEVA-ROSUVASTATIN
Report ID | 120250 |
Drug Identification Number | 02354624 |
Brand name | TEVA-ROSUVASTATIN |
Common or Proper name | ROSUVASTATIN 20MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | ROSUVASTATIN |
Strength(s) | 20MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 500 |
ATC code | C10AA |
ATC description | LIPID MODIFYING AGENTS, PLAIN |
Reason for shortage | Shortage of an inactive ingredient or component. |
Anticipated start date | |
Actual start date | 2020-07-13 |
Estimated end date | Unknown |
Actual end date | 2023-04-27 |
Shortage status | Resolved |
Updated date | 2023-04-28 |
Company comments | Allocating 100% of Teva market for duration of risk period. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v21 | 2021-05-06 | French | Compare |
v22 | 2023-04-27 | English | Compare |
v23 | 2023-04-27 | French | Compare |
v24 | 2023-04-28 | English | Compare |